China Pharma Holdings, Inc.
CPHI · New York Stock Exchange Arca · USD
0,565USD
−0,0049 (−0,86 %)Stand 9. Nov., 21:00
Vorbörslich0,55−0,015 (−2,65 %)4:16 ET
Kennzahlen
- Eröffnung
- 0,574
- Vortag
- 0,5699
- Tagesspanne
- 0,5601 – 0,60
- 52 Wochen
- 0,38 – 19,19
- Volumen
- 41.885
- Ø Volumen
- 4,2 Mio.
- Börsenwert
- 24,31 Mio. $
- KGV
- -0,6
- Gewinn je Aktie (TTM)
- -1,01
- Dividendenrendite
- 0,0 %
- Beta
- 1,0
- Nächste Zahlen
- –
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 4,14 Mio. | 4,53 Mio. | 7,01 Mio. | 8,1 Mio. | 9,64 Mio. |
| Herstellungskosten | 4,28 Mio. | 6,51 Mio. | 7,29 Mio. | 8,6 Mio. | 9,29 Mio. |
| Bruttogewinn | −131.950 | −1,99 Mio. | −281.085 | −493.916 | 349.270 |
| Forschung und Entwicklung | 280.901 | 283.942 | 240.080 | 185.858 | 318.964 |
| Vertrieb und Verwaltung | 2,83 Mio. | 2,31 Mio. | 2,25 Mio. | 2,96 Mio. | 3,15 Mio. |
| Operatives Ergebnis | −3,09 Mio. | −4,59 Mio. | −2,75 Mio. | −3,55 Mio. | −2,86 Mio. |
| EBITDA | −1,51 Mio. | −1,96 Mio. | 8435 | −837.689 | 230.345 |
| Nettogewinn | −3,19 Mio. | −4,74 Mio. | −3,08 Mio. | −3,97 Mio. | −3,4 Mio. |
| Gewinn je Aktie (verwässert) | -0,74 | -0,27 | -0,29 | -1,94 | -0,85 |
Umsatz nach Segment
Produkte · FY 2021
- DomesticPharmaceuticalsMember9,64 Mio. $100,00 %
Anteil · ggü. Vorjahr (FY 2020)
Bewertung
Letzte 12 Monate
- KGV
- -0,6
- Kurs-Umsatz-Verhältnis
- 6,2
- Kurs-Buchwert-Verhältnis
- 0,1
- PEG
- 0,0
- Bruttomarge
- −9,3 %
- Operative Marge
- −111,8 %
- Nettomarge
- −114,3 %
- Verschuldungsgrad
- 0,1
- EV/EBITDA
- -21,0
- Eigenkapitalrendite
- −17,1 %
- Kapitalrendite (ROIC)
- −10,8 %
- Free-Cashflow-Rendite
- −0,9 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | −3,2 % | −43,8 % | −4,0 % | −6,1 % | 3,6 % |
| Operative Marge | −74,5 % | −101,3 % | −39,2 % | −43,8 % | −29,7 % |
| Nettomarge | −76,9 % | −104,6 % | −43,9 % | −49,0 % | −35,3 % |
| KGV | -1,6 | -8,6 | -20,9 | -24,7 | -283,9 |
| Kurs-Umsatz-Verhältnis | 1,3 | 9,0 | 9,1 | 31,1 | 115,4 |
| Kurs-Buchwert-Verhältnis | 0,2 | 5,3 | 8,6 | 58,8 | 185,0 |
| Verschuldungsgrad | 0,2 | 0,5 | 0,6 | 2,0 | 2,1 |
| Liquidität 3. Grades | 0,3 | 0,7 | 0,9 | 0,5 | 0,9 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 8,73 Mio. | 43,65 Mio. | 67,34 Mio. | 259,06 Mio. | 1,12 Mrd. |
| EV/EBITDA | -5,8 | -22,2 | 7.983,0 | -309,3 | 4.865,4 |
| Eigenkapitalrendite | −14,0 % | −61,1 % | −41,3 % | −92,6 % | −56,5 % |
| Kapitalrendite (ROIC) | −11,3 % | −38,0 % | −21,4 % | −25,7 % | −14,8 % |
| Free-Cashflow-Rendite | 0,2 % | −1,9 % | −1,1 % | −0,3 % | −0,1 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −8,5 % | −35,4 % | −13,5 % | −15,9 % | −11,3 % |
| Bruttogewinn | +93,4 % | −606,4 % | +43,1 % | −241,4 % | −82,1 % |
| Operatives Ergebnis | +32,7 % | −66,8 % | +22,5 % | −24,1 % | −10,9 % |
| Nettogewinn | +32,7 % | −53,8 % | +22,5 % | −16,9 % | −18,6 % |
| Gewinn je Aktie | −174,1 % | +6,9 % | +85,1 % | −128,2 % | −18,1 % |
| Freier Cashflow | +101,5 % | −6,6 % | +12,4 % | −18,0 % | +24,4 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Aug. 2026 | Mai 2026 | Apr. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | März 2025 | Nov. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | -0,04 | -0,04 | -0,18 | -0,17 | -0,16 | -0,24 | -0,50 | -0,60 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 948.340 | 983.536 | 1,23 Mio. | 756.217 | 1,03 Mio. | 1,14 Mio. | 1,13 Mio. | 1,1 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 15. Apr. 20251:10
- 6. März 20241:5
- 6. März 20231:10
- 15. Aug. 2003250:5451
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 4,75 %
- Investoren mit 13F-Meldung
- 8
Größte Investoren
- CITADEL ADVISORS LLC2,92 %125.445
- TWO SIGMA SECURITIES, LLC0,83 %35.666
- RENAISSANCE TECHNOLOGIES LLC0,35 %15.045
- JANE STREET GROUP, LLC0,32 %13.886
- GROUND SWELL CAPITAL, LLC0,25 %10.610
- UBS GROUP AG0,07 %3109
- EFG INTERNATIONAL AG0,00 %40
- DANSKE BANK A/S0,00 %1
Insider-Geschäfte
- Liu Tao (Chengdu)28. Dez. 2023 · 10 percent ownerVerkauf0 Aktien
- Li Zhilin29. Sept. 2023 · director, 10 percent owner, officer: CEO & Interim CFOKauf13,76 Mio. Aktien · 0,14
- Deng Ke30. Dez. 2022 · 10 percent ownerVerkauf0 Aktien
- Li Zhilin9. Sept. 2021 · director, 10 percent owner, officer: CEO & Interim CFOKauf1,76 Mio. Aktien · 0,67
- Li Zhilin23. Dez. 2020 · director, 10 percent owner, officer: CEO and interim CFOKauf2 Mio. Aktien
- WAUNG FRANK28. Apr. 2012 · officer: Chief Financial OfficerKauf100.000 Aktien
- WAUNG FRANK25. Mai 2011 · officer: Chief Financial OfficerVerkauf25.000 Aktien · 2,54
- Li Zhilin25. Mai 2011 · director, 10 percent owner, officer: President and CEOKauf50.000 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
Führung
- Zhilin LiPresident, Chief Executive Officer, Chairman & Interim Chief Financial Officer
- Huang NaBOD Secretary & IR Manager
- CEO
- Zhilin Li
- Mitarbeitende
- 215
- Hauptsitz
- Haikou, HA, CN
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 17. Apr. 2002
- Website
- chinapharmaholdings.com
Nachrichten
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.